Dr. Leigh Vinocur, Top Cannabis Physician, Explains CBD Pilot
In this episode of Trade To Black, presented by Flowhub, hosts Shadd Dales and Anthony Varrell break down the new Medicare CBD pilot program — and why it could end up being one of the more important federal developments we’ve seen in years. For the first time, the U.S. government is testing a structured model where Medicare patients can receive a $500 annual benefit card to purchase qualifying hemp-derived CBD products. This is tied directly to the 2027 Medicare rule — so this isn’t theoretical, it’s a real pilot that’s been put in motion. To help make sense of it, Dr. Leigh Vinocur joins the show — one of the leading cannabis physicians in the country and a member of the National Cannabis Care Council (NCCC).
This isn’t just a surface-level conversation — we get into how this actually works for patients, what kind of physician oversight is involved, and what CMS is ultimately trying to measure through this program. But the bigger question is this: Is this just a contained pilot… or an early step toward cannabinoids being integrated into the U.S. healthcare system? Because if this expands beyond 2027 — the implications for companies, investors, and policy are significant.
Dr. Vinocur contextualized the pilot within decades of policy failure, noting that Nixon ignored his own Schaeffer Commission’s finding that cannabis was not particularly dangerous when he signed the Controlled Substances Act in the 1970s. She emphasized that hemp and cannabis are botanically the same plant, separated only by a federal definition, and that the program’s allowance of up to three milligrams of THC in products — administered through Medicare’s accountable care organization framework — represents a meaningful federal acknowledgment that cannabinoids have therapeutic value.
She identified chronic pain and cancer pain as the primary conditions CMS will be tracking, and stressed that the program’s success will depend heavily on knowledgeable physicians and support staff who can properly titrate dosing for senior patients rather than simply handing them a product and sending them home. Real-world data collection, she argued, is among the most valuable outputs the pilot can generate, given how difficult it has been to conduct standardized cannabis research under Schedule 1 restrictions.
On the broader regulatory picture, Dr. Vinocur expressed hope that rescheduling would free up clinical research and allow for the development of standardized cannabinoid medicines, drawing comparisons to how other countries — particularly Germany, Israel, and Canada — have moved far ahead of the United States. She was measured but critical of the looming federal hemp ban, arguing that while synthetic and exotic cannabinoids deserve to be reined in, reputable full-spectrum CBD companies serving patients should not be swept away in the process.
